Cargando…

Biomarkers of Aggressive Prostate Cancer at Diagnosis

In the United States, prostate cancer (CaP) remains the second leading cause of cancer deaths in men. CaP is predominantly indolent at diagnosis, with a small fraction (25–30%) representing an aggressive subtype (Gleason score 7–10) that is prone to metastatic progression. This fact, coupled with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boehm, Brock E., York, Monica E., Petrovics, Gyorgy, Kohaar, Indu, Chesnut, Gregory T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916581/ https://www.ncbi.nlm.nih.gov/pubmed/36768533 http://dx.doi.org/10.3390/ijms24032185

Ejemplares similares

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
por: Kohaar, Indu, et al.
Publicado: (2019)

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men
por: Duncan, Allison, et al.
Publicado: (2023)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities
por: Tan, Shyh-Han, et al.
Publicado: (2018)

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes
por: Kohaar, Indu, et al.
Publicado: (2022)

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men
por: Petrovics, Gyorgy, et al.
Publicado: (2015)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Oncogenic activation of ERG: A predominant mechanism in prostate cancer
por: Sreenath, Taduru L, et al.
Publicado: (2011)

Evaluation of protein biomarkers of prostate cancer aggressiveness
por: Rizzardi, Anthony E, et al.
Publicado: (2014)

Novel approaches for the identification of biomarkers of aggressive prostate cancer
por: Kim, Yunee, et al.
Publicado: (2013)

Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer
por: Eickelschulte, Samaneh, et al.
Publicado: (2022)

Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men
por: Farrell, James, et al.
Publicado: (2013)

Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
por: Santos, Pedro Bargão, et al.
Publicado: (2020)

Prostate stem cell antigen (PSCA) and risk of bladder cancer: linking genotypes to functional mechanisms
por: Mumy, Adam, et al.
Publicado: (2011)

Blood-Based Biomarkers of Aggressive Prostate Cancer
por: Liong, Men Long, et al.
Publicado: (2012)

Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer
por: Wang, Ce, et al.
Publicado: (2022)

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population
por: Petrovics, Gyorgy, et al.
Publicado: (2018)

Emerging biomarkers in the diagnosis of prostate cancer
por: Filella, Xavier, et al.
Publicado: (2018)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

Modern biomarkers in prostate cancer diagnosis
por: Porzycki, Paweł, et al.
Publicado: (2020)

Biomarkers for Prostate Cancer: From Diagnosis to Treatment
por: Chen, Jia-Yan, et al.
Publicado: (2023)

Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness
por: Giskeødegård, Guro F., et al.
Publicado: (2013)

The Role of Adhesion Molecules as Biomarkers for the Aggressive Prostate Cancer Phenotype
por: Morgan, Claire, et al.
Publicado: (2013)

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer
por: Martínez-González, Luis Javier, et al.
Publicado: (2021)

The potential of miR-153 as aggressive prostate cancer biomarker
por: Gilyazova, Irina, et al.
Publicado: (2022)

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India
por: Rawal, Sudhir, et al.
Publicado: (2013)

Prostate cancer gene expression signature of patients with high body mass index
por: Sharad, Shashwat, et al.
Publicado: (2010)

ARHGEF38 as a novel biomarker to predict aggressive prostate cancer
por: Liu, Kun, et al.
Publicado: (2019)

Aggressive Prostate Cancer in Patients Treated with Active Surveillance
por: Tohi, Yoichiro, et al.
Publicado: (2023)

Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis
por: Di Francesco, Simona, et al.
Publicado: (2013)

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
por: Bertoli, Gloria, et al.
Publicado: (2016)

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer
por: Sahoo, Debashis, et al.
Publicado: (2018)

PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
por: Ilboudo, Adeodat, et al.
Publicado: (2015)

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer
por: Song, Jin, et al.
Publicado: (2021)

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
por: Shipitsin, M, et al.
Publicado: (2014)

Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression
por: Rybak, Adrian P., et al.
Publicado: (2014)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
por: Merkens, Lina, et al.
Publicado: (2022)

Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
por: Matuszczak, Milena, et al.
Publicado: (2021)

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
por: Thoms, J W, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dsfel725nrrbfs0sh0up5i9iu8